IGFBP7 and breast carcinoma: Our observation that that high IGFBP7 expression was associated with worse clinical outcome in SCAN-B, a large contemporary population-based breast cancer cohort unexposed to ganitumab, supports the concept that high IGFBP7 expression reveals more than increased resistance to ganitumab.